China channel feed – Endpoints News

SIGN UP

China channel feed

Chinese cell therapy biotech developing TIL therapies raises $60M Series B

3 weeks ago

ABVC BioPharma to break ground in China, advances 20% stake in Zhonghui real estate

Last month

Innoforce names Dewan Zeng as the new CEO

Last month

Merck KGaA, MilliporeSigma make investments in the US and China manufacturing

2 months ago

Updated: FDA to import more of common cancer drug from China after Indian site closure

2 months ago

BeiGene further invests in ADCs with solid tumor partner DualityBio, a BioNTech collaborator

2 months ago

WuXi Biologics seeks spinout, HK listing of bioconjugates-focused joint venture

2 months ago

China approves BCMA CAR-T therapy for multiple myeloma, with Innovent beating Legend in race to be first

2 months ago

CSPC to launch Paxlovid version in China; SEC charges ex-Pfizer employee with insider trading

3 months ago

Touting programs from Novartis, Laekna bags $100M in Hong Kong IPO while Merck-partnered Kelun seeks up to $208M

3 months ago

AstraZeneca ponders a China pharma spinoff to protect itself from geopolitical fallout — FT

3 months ago

AstraZeneca enlists an upstart China biotech partner in the wake of an R&D setback

3 months ago

Eccogene nabs $25M Series B for GLP-1 and a NASH drug candidate, as competitors lap the China biotech

3 months ago

Fosun Pharma to receive $100M+ via World Bank for facility in Ivory Coast

3 months ago

FDA inspection of China-based site making Coherus' potential new cancer drug ends with three observations

4 months ago

China's market regulator fines, confiscates revenue from pharmas for monopolizing APIs for epinephrine

4 months ago

C4 Therapeutics gets $35M from Betta Pharmaceuticals to develop and market NSCLC drug in China

4 months ago

XtalPi inks $250M pact with Lilly after Pfizer success

4 months ago

Innovent showcases topline PhII win for high-dose obesity drug in China

4 months ago

Roche hands Chinese biotech $70M for HER2 drug that can go to the brain

4 months ago

Eisai’s cancer drug Halaven at the center of $2B pact with BlissBio, like its Bristol Myers ADC deal

4 months ago

Chinese biotech startup adds $315M to the bank after bringing 5 Takeda drugs to its fold

5 months ago

Pyramid inks TROP2 pact with China biotech to follow suit of Gilead, AstraZeneca-Daiichi Sankyo

5 months ago

Pharmaron expanding Liverpool manufacturing facility with a $186M+ price tag

6 months ago

12 3 4 Next page Last page